admin
A newly published interagency agreement — posted by a news outlet alongside an 8‑page PDF — shows the CIA’s Biological Technology Center quietly working with the National Institute of Allergy and Infectious Diseases. The document says the CIA would help NIAID obtain biological sample sets, support “forensic microbiology” research using civilian genomics capacity, and reserve approval over who sees the technical data, even when it’s marked “sensitive, but unclassified.”
What the document actually says
The PDF is stamped UNCLASSIFIED//FOUO and is titled as a “Statement of Work For Bioforensics R&D technical support.” It names the CIA BTC as supporting forensic microbiology R&D for the intelligence community and explicitly directs the BTC to “facilitate NIAID obtaining sample sets from other US Government entities as appropriate.” In plain English, an intelligence arm offered to help a civilian research outfit get biological samples — what the document calls “germs” in reporting — and then said it would control who could share the results. The contract also instructs that deliverables be labeled “For Official Use Only,” and a data‑rights clause gives the CIA veto power over disclosure.
Why Americans should care
This isn’t garden‑variety lab cooperation. It raises real oversight and ethical questions about how intelligence agencies and public health institutions mingle around biological agents. After whistleblower testimony that “the lines between public health and biodefense have been blurred beyond recognition,” and Senate hearings where Dr. Anthony Fauci, former Director of NIAID, faced tough questions, this document is more than a curiosity — it’s evidence the blur may have been by design. Senator Rand Paul and others demanding accountability have a clear reason to press for documents, contracts, and testimony explaining who knew what and when.
Questions Congress should demand answers to
Start with the basics: when was this agreement executed and what funds moved where? Which agencies supplied the sample sets, who handled them, and which private partners were involved? Did any samples leave U.S. labs or go to contractors with commercial ties? Who signed off on the CIA’s data‑control clause, and under what legal authority can an intelligence agency lock down supposedly civilian research by marking it “sensitive, but unclassified”? If committees won’t get voluntary answers, subpoenas should follow — Americans deserve clear lines between public health research and covert intelligence work, not paperwork that creates secrecy by euphemism.
Bottom line: transparency isn’t optional
The newly published PDF is a fresh development that sits on top of existing congressional scrutiny. It ought to trigger straightforward oversight: confirm the document’s provenance, reveal the dates and money flows, and produce the records showing how samples were handled and who gained access to the research. Vague labels and back‑door arrangements don’t protect the public — they protect the institutions that want to avoid tough questions. If the CIA and NIAID had good reasons for this work, those reasons should be explained publicly. If not, Congress should make them explain themselves under oath.
